New Delhi: India’s Zydus Cadila has sought DCGI (Drugs Controller General of India) nod to undertake clinical trials of its antibody cocktail that can neutralise Covid infection.
ZRC-3308 is a cocktail of 2 anti-SARS-CoV-2 monoclonal antibodies.
The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials, the drugmaker said, adding it was found to be safe and well-tolerated.
The therapy is a cocktail of two monoclonal antibodies, which mimic natural antibodies that the body generates to fight infection.
Zydus is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID-19, it said. Zydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI.
The US Food and Drug Administration has given emergency use authorisations to similar treatments developed by Vir Biotechnology and GlaxoSmithKline as well as ones made by Regeneron Pharmaceuticals and Eli Lilly.
